An Evaluation of Use of Topical Ocular Hypotensive Medication by Compliance
Status:
Completed
Trial end date:
2006-04-01
Target enrollment:
Participant gender:
Summary
This is an open-label study in patients who are currently using either a topical
prostaglandin as sole ocular hypotensive medical therapy q.d., or a topical prostaglandin
plus an adjunctive topical ocular hypotensive marketed product either q.d., or b.i.d. in the
same eye(s). Compliance will be measured over the two months of participation.